Adial announces publication of international patent application for AD04

Adial Pharmaceuticals (ADIL) announced the publication of the international patent application for AD04, filed in July 2024. AD04 is the Company’s lead investigational genetically targeted serotonin-3 receptor antagonist therapeutic agent for the treatment of Alcohol Use Disorder in heavy drinking patients. The patent, once granted, is expected to protect Adial’s core assets through at least 2045. Cary Claiborne, President and Chief Executive Officer of Adial, commented, “As we continue to advance the AD04 program with planning for the next phase of our clinical program, the new patent application and its expected approval will extend protection of the core assets of Adial out to at least 2045. This application is the result of an extensive examination of data and information which occurred after Adial hired new patent counsel to bolster and leverage Adial’s intellectual property portfolio.”